Literature DB >> 24637315

Focal radiotherapy as focal therapy of prostate cancer.

György Kovács1, Jean-Marc Cosset, Brendan Carey.   

Abstract

PURPOSE OF REVIEW: Focal radiotherapy treatment procedures play an increasingly important role in function-preservation and organ-preservation treatment techniques. As an alternative to traditional whole-gland radiotherapy regimes, focal prostate radiotherapy may be of benefit for both primary tumor as well as locally recurrent disease. This is a review of the current literature on the topic, including patient selection, preliminary toxicity, and outcome data as well as a technical overview on treatment delivery techniques. RECENT
FINDINGS: Partial organ treatment in early prostate cancer (PCa) is now technically feasible with both newer external-beam and brachytherapy technology. To date, only small and generally monoinstitutional series have been published in the literature. Early feasibility and toxicity data are encouraging, and demonstrate potential advantages for the role of focal brachytherapy in early PCa. Although some advanced external-beam techniques can also be used to deliver focal therapy within the prostate, there is no relevant publication in the literature.
SUMMARY: Radiotherapy, especially interventional radiotherapy (brachytherapy), is a technically feasible treatment technique to deliver focal radiotherapy for PCa. To date, only preliminary results are available for all forms of interventional radiotherapy (high dose rate, low dose rate, and pulsed dose rate) for focal PCa treatment and no large cohort comparative results are published. As interventional radiotherapy (brachytherapy) as yet lacks any such long-term studies, comparative outcome data are not available to suggest differences in efficacy for one form of brachytherapy or another.

Entities:  

Mesh:

Year:  2014        PMID: 24637315     DOI: 10.1097/MOU.0000000000000042

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  6 in total

1.  Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.

Authors:  Henk van der Poel; Laurence Klotz; Gerald Andriole; Abdel-Rahmène Azzouzi; Anders Bjartell; Olivier Cussenot; Freddy Hamdy; Markus Graefen; Paolo Palma; Arturo Rodriguez Rivera; Christian G Stief
Journal:  World J Urol       Date:  2015-06-03       Impact factor: 4.226

Review 2.  Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI.

Authors:  M J Connor; M A Gorin; H U Ahmed; R Nigam
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-02-12       Impact factor: 5.554

Review 3.  Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project.

Authors:  B G Muller; W van den Bos; M Brausi; J J Fütterer; S Ghai; P A Pinto; I V Popeneciu; T M de Reijke; C Robertson; J J M C H de la Rosette; S Scionti; B Turkbey; H Wijkstra; O Ukimura; T J Polascik
Journal:  World J Urol       Date:  2015-01-06       Impact factor: 4.226

4.  [Organ and function preservation in prostate cancer].

Authors:  M Fröhner; M Wirth
Journal:  Urologe A       Date:  2014-09       Impact factor: 0.639

5.  Second salvage treatment for local recurrence of prostate cancer using high-dose-rate brachytherapy: a case report.

Authors:  Audrey Claren; Mathieu Gautier; Julien Feuillade; Alexander Tuan Falk; Jean-Michel Hannoun Levi
Journal:  J Contemp Brachytherapy       Date:  2015-05-28

6.  Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database.

Authors:  Nikola Cihoric; Alexandros Tsikkinis; Cristina Gutierrez Miguelez; Vratislav Strnad; Ivan Soldatovic; Pirus Ghadjar; Branislav Jeremic; Alan Dal Pra; Daniel M Aebersold; Kristina Lössl
Journal:  Radiat Oncol       Date:  2016-03-22       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.